TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ-related pathology. At this early time point, Aβ accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which may represent dystrophic neurons that accumulate over time as a result of ineffective microglial control of AD pathology due to lack of Trem218,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the compaction of protofibrillary Aβ into a dense core plaque, which requires apoE and is promoted by TREM2 (Bales et al., 1997b, 1999; Bien-Ly et al., 2012; Wang et al., 2016; Yuan et al., 2016), could be a protective mechanism that limits neurotoxicity of amyloid deposits once they start to build up in the aging brain.”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trem2 deficiency induces dynamic changes but an eventual increase in plaque and neuritic pathology (Jay et al., 2017; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction48,49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [48]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013).”
BackgroundMethodInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“However, phenotypic markers of migroglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 11×
“…response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synapse loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011).”
BackgroundSelf-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguero et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia.”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 2×
“TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727 · cited 2×
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
Background
Cited by
Items 801–838 of 838
Protocol for the quantification of digestive exophagy in cell culture
Funes, L., Maxfield, F. R., & Solé‐Domènech, S. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104355
Kerslake, L. D., Noonan, C., Davies, D., Kim, D., Eshou, V. A., Goldsbury, C. S., & Cullen, K. M. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.03.004
Inflammatory Mediators Both Directly and Indirectly Promote Microglial Proliferation
Hammond, B. P., Hahn, E., Lee, K. V., Kerr, B. J., & Plemel, J. R. (2026) · Glia · doi:10.1002/glia.70150
“For example, in Alzheimer's disease models, microglia proliferate near, and subsequently surround, amyloid plaques so they may phagocytose amyloid and limit neuritic dystrophy (Condello et al. 2015; Olmos-Alonso et al. 2016; Wang et al. 2016).”
Kim, D., Kondo, T., Imamura, K., Tsukita, K., Nagahashi, A., Sakasai, T., & Inoue, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71074 · Cited by 1
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Mechanisms controlling microglial colonization of the forebrain
Bridlance, C. (2023) · theses.fr (ABES) · doi:10.70675/5879aa36z8649z48f9zb359zf349ce3cb429
Moreira-de-Sá, A. (2024) · theses.fr (ABES) · doi:10.70675/3e418ab2ze9a3z43e4z9d87ze5870aefddac
Alam, J., Kalash, A., & Reyaz, S. (2026) · Advanced Neurology · doi:10.36922/an025460115
Targeting microglia: A new strategy for the treatment of Alzheimer's disease
Zheng, M., Yang, M., Su, W., Tian, L., & Gao, W. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.578966
Zou, Y., Lin, Y., Zhang, C., Li, Y. L., Chen, X., Ma, X., Chen, K., Liang, B., & Liang, P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1839602 · Cited by 1
“Microglia, the resident macrophages of the brain, are primarily responsible for degrading A β (Kimura et al., 2025; Wang et al., 2016; Yuan et al., 2016).”
Shang, X., Maimaiti, N., Tian, F., 廖春波, Sun, H., Zhou, X., Kong, W., Sun, Q., Wang, L., & Ma, X. F. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1835965
“…in neuroin fl ammation, upregulated TREM2 drives the transition of microglia from an M1 to an M2 phenotype, thereby exerting neuroprotective effects (Wang et al., 2016); similarly, during viral respiratory infections, TREM2 enhances IL-3 production and promotes M2 polarization of lung macrophages…”
Papageorgopoulou, M., Adair, E., Fancy, N. N., Avot, B., Boulger, S. L., Wülfing, M. S., & Matthews, P. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.733103
“Impaired microglial activation, such as is associated with TREM2 haplodeficiency or loss of function variants, leads to more diffuse plaques and increased neuritic damage 17,18 .”
Shirotani, K., Hatta, D., Watanabe, K., Saito, T., Saido, T. C., & Iwata, N. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115894 · Cited by 1
Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer’s disease
Wu, J., Zhao, J. J., Chen, S. Y., & Xu, F. (2026) · Biological Research · doi:10.1186/s40659-026-00716-8
Piłat, D., Baranger, K., & Rivera, S. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.07.004
Shirotani, K., Hatta, D., Watanabe, K., Saito, T., Saido, T. C., & Iwata, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.724708
“…(KO) impairs microglial clustering (Jay et al., 2015; Meilandt et al., 2020; Wang et al., 2015) and barrier function around amyloid plaques (Wang et al., 2016; Yuan et al., 2016), enhances Aβ accumulation (Jay et al., 2017; Wang et al., 2015) and seeding of Aβ plaques (Parhizkar et al.,…”
InfluentialLiu, L., Xiao, H., Zhou, J., Zhang, M., & Duan, J. (2026) · PeerJ · doi:10.7717/peerj.21359
“The triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor that is speci fi cally localized on the membranes of MG and plays a critical role in modulating neuroin fl ammatory responses in the CNS ( Wang et al., 2016 ).”
The human retina in Alzheimer’s disease: Pathology, mechanisms, and biomarkers
Müller, L. P. D. S., Majumdar, S., & Recio, B. S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103275
Li, Q., Li, M., Huang, X., Cao, C., & Hu, Y. (2026) · Immunobiology · doi:10.1016/j.imbio.2026.153229
Hossain, M. M., Adhikari, J., Fardous, J., Ahmed, S., Ferdous, M. T., & Shibly, A. Z. (2026) · Next research. · doi:10.1016/j.nexres.2026.102314
Targeting Microglial Receptors for Alzheimer’s Disease: Translational Barriers from Bench to Bedside
Tang, X., Hasan, I., & Xu, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0008
Shi, L., Zhou, C., Han, H., Lu, M., Li, M., Junjing, M., Feng, S., Zhou, X., Chen, H., & Ren, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1925850
“Early microglial responses were initially considered protective, as they can restrain plaque growth and limit amyloid-associated neuronal injury (19).”
The role of microglia glucose metabolism reprogramming in Alzheimer's disease treatment
Cao, Q., Shen, M., Liu, Y., Li, C., Liu, L., Zhou, J., Yue, R., Niu, D., Ren, Y., Pan, L., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261478594
“68 In the late stage, microglia exhibit features of “ immune tolerance ” or “ functional exhaustion, ” characterized by the dual downregulation of both glycolytic and OXPHOS capacities, 69 mitochondrial dysfunction, 66,70,71 and signi fi cantly impaired phagocytic ability.”
TREM2-directed therapy in Alzheimer’s disease: from therapeutic window to clinical translation
Kuang, Q., Li, S., Huang, W., Kuang, N., Liu, T., Huang, N., Luo, Y., & Huang, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1938062
“In this setting, TREM2 is closely involved in plaque sensing, microglial recruitment, and plaque-associated barrier formation (Wang et al., 2016; Zhong et al., 2018; Magno et al., 2021).”
InfluentialIntharuksa, A., Prasansuklab, A., Techarang, T., Chaikhong, K., Arunotayanun, W., & Jenraumjit, R. (2026) · Nutrients · doi:10.3390/nu18193126
“In experimental models, this plaque-associated microglial response has been shown to increase plaque compaction and limit local neuritic damage, particularly during early stages of amyloid deposition [15,17,18].”
Oon, C. H., Levitt, E. M., Shapiro, D. A., O’Brien, C. A., Davis, M. R., Shestova, O., Axsom, J., Yaqoob, F., Lomeikaitė, V., Koumadorakis, D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10963419/v1
Yu, X., Ren, Q., Gao, Y., Xie, S., Dang, R., Meng, J., Su, Z., Li, M., Ao, Y., Liu, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118063 · Cited by 1
Self-citationThe microglial lineage: from molecular states to context-dependent functions
Li, C., Wu, Z., Xiang, X., & Li, H. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100378
“TREM2-dependent microglia surround early plaques, restrict amyloid diffusion, compact the deposits and reduce the exposure of nearby neurites to fibrillar A β (Wang et al., 2016; Yuan et al., 2016).”
Bermudez, S., Choi, J.-H., Mahmood, N., Vogel, J. W., Almousa, H. A., Huang, Z., Kim, S.-H., Zhu, V. Y., Zhou, L., Casas-Antillon, D., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2610766123
TREM2 Signaling and Alzheimer’s Disease: Experimental Modulators, Progress, and Challenges
Sayegh, M., Azarfar, K., Reyna, E. M., Kennedy, J. M., Sabbagh, M. N., & Decourt, B. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s611558
Ding, L., Yu, W., Chen, Y., Wang, H., Li, S., Li, H., Shu, T., Huang, X., Yang, Y., Liu, R., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71215
Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis
Walsh, A. E., Davis, B. A., Samuels, J. D., Mills, W. A., Thanos, J. M., Johnson, A. M., Moore, K. A., Puchalski, M. A., Steacy, E. J., Wendell, B. W., et al. (2026) · Journal of Experimental Medicine · doi:10.1084/jem.20260104
“…comparison with the recent advancements made in defining roles for innate immune pattern recognition receptors (e.g., TREM2, CLEC7A) and cytokine signaling (e.g., IL-1, type I IFN) in AD (Keren-Shaul et al., 2017; Mangalmurti et al., 2025; McQuade et al., 2020; Wang et al., 2016; Yoo et al., 2023).”
Metadata
- Authors
- Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R. B., Cirrito, J. R., Holtzman, D. M., & Colonna, M.
- Affiliations
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-04-18
- Volume
- 213
- Issue
- 5
- Pages
- 667-675
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4854736
- OpenAlex
- W2339534121
- Cited by
- 840
- References
- 32
- Citations by year
- 2026: 62 · 2025: 76 · 2024: 86 · 2023: 106 · 2022: 114 · 2021: 102 · 2020: 93 · 2019: 73 · 2018: 61 · 2017: 50 · 2016: 16
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (RF1 AG05148501, 5T32CA009547-30, AG047644)
- National Multiple Sclerosis Society (RG4687A1/1)
- Cure Alzheimer’s Fund
- JPB Foundation
- Knight Alzheimer’s Disease Research Center (P50 AG005681-30)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, microglia, amyloid plaques, Alzheimer's disease, parabiosis, 5xFAD mice, TREM2 deficiency, lipid microenvironment, peripheral blood monocytes
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Membrane Glycoproteins, Monocytes, Receptors, Immunologic, Amyloid beta-Peptides, Neurites, Microglia, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.